Dissolvable polymeric eye inserts and method of using same
Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more polymers as well as a softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. Increased retention time on the ocular surface for longer lasting relief may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.
1. A polymeric eye insert, the insert comprising:
mucoadhesive polymers that are biocompatible with the ocular surface and tear film of the eye and a plasticizer or softener, wherein the mucoadhesive polymers are a combination of HP guar, hyaluronic acid, or sodium hyaluronate and polyvinyl pyrrolidine, wherein the mucoadhesive polymers are present in an amount of from 80% to 90% w/w of the polymeric eye insert, wherein a plasticizer or softener is polyethylene glycol (PEG); and wherein upon insertion of the polymeric eye insert in the cul-de-sac of the eye, the thickness of the tear film increases for at least 30 minutes post-insertion.
2. The polymeric eye insert of claim 1 , wherein the plasticizer or softener is present in an amount of from 5% to 25% w/w of the polymeric eye insert.
3. The polymeric eye insert of claim 1 , wherein the insert is comprised of approximately 40% w/w HP guar, approximately 10% w/w PVP, approximately 40% w/w sodium hyaluronate, and approximately 10% w/w PEG.
4. The polymeric eye insert of claim 1 , further comprising 1-200 ppm menthol.
5. The polymer eye insert of claim 4 , comprising 20-100 ppm menthol.
6. The polymeric eye insert of claim 1 , wherein the insert comprises one or more pharmaceutically active agents.
7. The polymeric eye insert of claim 5 , wherein the one or more pharmaceutically active agents is selected from the group consisting of atropine derivatives which are not nitric oxide donors, travoprost co-drug with nitric oxide, lubricants, steroids, antibiotics, nonsteroidal anti-inflammatory drugs, anti-histamines, anti-virals, anti-bacterials, vasoconstrictors, and prostaglandin analogs.
8. The polymeric eye insert of claim 1 , wherein the tear film thickness does not return to pre-insertion thickness until approximately two hours after insertion.
9. The polymeric eye insert of claim 1 , wherein upon insertion in the cul-de-sac of the eye, the thickness of the tear film increases up to at least two hours post-insertion.
10. The polymeric eye insert of claim 1 , wherein the insert shape is a film.
11. The polymeric eye insert of claim 1 , wherein said HP guar has a weight average molecular weight of 2 to 4 million Daltons and said sodium hyaluronate has a weight average molecular weight of 0.1 to 2 million Daltons.
12. A method of treating an ocular disorder, which comprises applying the polymeric eye insert of claim 1 to the cul-de-sac of the eye, wherein said ocular disorder is selected from the group consisting of dry eye, eye redness, myopia, glaucoma, allergy, and inflammation.